Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Antimicrobial agents and chemotherapy - 1 Apr 2011

Selhorst Philippe, Vazquez Ana C, Terrazas-Aranda Katty, Michiels Johan, Vereecken Katleen, Heyndrickx Leo, Weber Jan, Quiñones-Mateu Miguel E, Ariën Kevin K, Vanham Guido

Abstract excerpt

Microbicides based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) are currently being developed to protect women from HIV acquisition through sexual contact. However, the large-scale introduction of these products raises two major concerns. First, when these microbicides are used by u...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Infective Agents

Share to Benzoxazines

Share to Cyclopropanes

Share to Furans

Share to Nevirapine

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 21282453
DOI: 10.1128/AAC.01426-10
PMCID: PMC3067143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21282453-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.PMID 21282453Read ↗

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Semantic proximity Read ↗

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.Semantic proximity Read ↗

Understanding transmitted HIV resistance through the experience in the USA.Semantic proximity Read ↗

Nonnucleoside Reverse Transcriptase Inhibitor ResistanceSemantic proximity Read ↗

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.Semantic proximity Read ↗

Nonnucleoside Reverse Transcriptase Inhibitor ResistanceSemantic proximity Read ↗

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Semantic proximity Read ↗

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.Semantic proximity Read ↗

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Semantic proximity Read ↗

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.